Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.31 Bil Enterprise Value: 13.36 Bil PE Ratio: 70.93 PB Ratio: 2.84 GF Score: 62/100

Biomarin Pharmaceutical Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 04:40PM GMT
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

Okay. Good morning, everyone. From the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov, I'm the senior large-cap biotech analyst, and it's my pleasure to introduce our next company, BioMarin. As you can see on your screens here, we have quite the contingent. So in addition to J.J. Bienaime, the Chairman and CEO; Hank Fuchs, President of Worldwide Research and development; Jeff Ajer, Executive Vice President and Chief Commercial Officer; Greg Guyer, Executive Vice President and Chief Technical Officer; Brian Mueller, EVP and Chief Financial Officer; and Lon Cardon, SVP and Chief Scientific Strategy Officer.

So they'll all be here for Q&A in addition to some of the slides towards the end. (Operator Instructions)

So with that, J.J., thank you for being here today. Let me hand things off to you.

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Thank you, Cory. Good morning or good afternoon,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot